Group 1 - The company is engaged in ongoing and constructive discussions with the U.S. administration regarding Medicaid exposure, indicating a proactive approach to policy changes [1][2] - The senior team is actively meeting with key stakeholders in Washington D.C., emphasizing the importance of these relationships in navigating the regulatory landscape [2] - The administration aims to avoid actions that could harm the sector and innovation, suggesting a supportive environment for companies in the industry [3]